Stifel raises target for Mirum Pharmaceuticals stock to USD 156

Mirum Pharmaceuticals (US6047491013) received a higher Stifel price target of USD 156.00 on October 15, 2026, up from USD 136.00, while the firm kept its Buy rating, according to Investing.com. On Nasdaq, the stock was trading at USD 85.36 on October 20, 2026 at 1:43 p.m. ET, placing the Stifel target 82.75 percent above that price. Mirum Pharmaceuticals was trading at EUR 76.03 at Lang & Schwarz on October 20, 2026 at 7:39 p.m. CEST.

Revenue beats estimates despite loss

The latest reported operating figure gives the analyst view a concrete counterweight. Mirum reported USD 176.24 million of revenue for the second quarter of 2026, versus a consensus estimate of USD 166.33 million, while adjusted earnings per share were not the issue: GAAP earnings per share came in at a loss of USD 1.06 against a consensus loss of USD 0.74, according to MarketBeat. Revenue therefore exceeded consensus by 5.96 percent, but the earnings shortfall underlines the gap between commercial growth and current profitability.

Stock remains below its yearly high

Mirum's Nasdaq range was USD 63.23 to USD 130.00 as of October 20, 2026. The USD 85.36 market price stood 34.34 percent below the 52-week high and 35.01 percent above the 52-week low. Trading volume was 219,129 shares at the same market timestamp, while the company carried a market capitalization of USD 5.5 billion.

What comes before the next report?

The next scheduled corporate date is November 3, 2026, when Mirum is estimated to report third-quarter results after the market close, with a conference call scheduled for 4:30 p.m. ET, according to MarketBeat. Consensus estimates call for USD 178.06 million in revenue and a loss of USD 0.4873 per share for that quarter. The figures make revenue execution and the size of the loss the clearest tests for the elevated analyst valuation.

Comparison with peers

Mirum Pharmaceuticals: 3.80 percent, P/E -5.87, market capitalization USD 5.5 billion. Bristol-Myers Squibb: 4.61 percent, P/E 13.55, market capitalization USD 125.7 billion. Alnylam Pharmaceuticals: minus 0.57 percent, P/E 39.18, market capitalization USD 31.0 billion.

Price and valuation

Stifel's USD 156.00 target is substantially above the Nasdaq trading price, while the current negative P/E reflects Mirum's reported loss rather than a profitable earnings base. The company operates in biotechnology and develops treatments for rare liver and gastrointestinal diseases, with LIVMARLI as its lead commercial product.

The further course of trading is shown by the continuously updated real-time quote of Mirum Pharmaceuticals stock.

Market context: Market report S&P 500.

More news and analyses on Mirum Pharmaceuticals stock